Stocks Health care NRIX
NASDAQ · Health careNurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics, Inc. brought in $701.9M of revenue over the twelve months to August 31, 2026, up 738.8% from a year earlier. Net income was $294.9M, a net margin of 42.0%. In fiscal 2025 capital spending exceeded operating cash flow by $263.5M. At August 31, 2026 it held $720.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 13, 2026.
Key facts about Nurix Therapeutics, Inc.
- Net worth
- Nurix Therapeutics, Inc. has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $968.3M on its balance sheet at August 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $84M (+54.0% year on year), with a net loss of $264.5M. Over the 12 months to August 31, 2026: revenue $701.9M, net income $294.9M.
- Cash flow
- In fiscal 2025 operations used $249.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 13, 2026 and covers the period to August 31, 2026. Open on SEC EDGAR
- Next earnings report
- Nurix Therapeutics, Inc.'s next report is expected around January 27, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Nurix Therapeutics, Inc. does
Nurix Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NRIX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $84M | -$264.5M | -$3.05 | -$263.5M |
| 2024 | $54.5M | -$193.6M | -$2.88 | -$181.9M |
| 2023 | $77M | -$143.9M | -$2.65 | -$89.8M |
| 2022 | $38.6M | -$180.4M | -$3.71 | -$172.1M |
| 2021 | $29.8M | -$117.2M | -$2.73 | -$90M |
| 2020 | $17.8M | -$43.2M | -$2.76 | -$4.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where NRIX ranks in Health care
Latest SEC filings
What Nurix Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 3, 2026Other event 8-K
- October 13, 2026Quarterly report 10-Q · period to August 31, 2026Revenue rose 8,426% to $673.1M versus the same quarter last year; diluted EPS $4.73 versus -$1.03.
- October 13, 2026
- September 23, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Nurix Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.7M worth of shares in the last 90 days and bought none on the open market. Most of the selling (59%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 4, 2026 | van Houte HansChief Financial Officer | Soldpre-planned (10b5-1) | 3,300 | $50.8K |
| November 4, 2026 | van Houte HansChief Financial Officer | Soldpre-planned (10b5-1) | 1,469 | $23.8K |
| November 3, 2026 | Ring ChristineChief Legal Officer | Soldpre-planned (10b5-1) | 6,113 | $157.9K |
| November 2, 2026 | Ring ChristineChief Legal Officer | Exercised options | 5,786 | $50.5K |
| November 2, 2026 | Ring ChristineChief Legal Officer | Soldpre-planned (10b5-1) | 9,527 | $245.2K |
| November 2, 2026 | Ring ChristineChief Legal Officer | Soldpre-planned (10b5-1) | 1,075 | $28.8K |
| November 2, 2026 | Hansen GwennChief Scientific Officer | Exercised options | 1,452 | $2.7K |
| November 2, 2026 | Hansen GwennChief Scientific Officer | Soldpre-planned (10b5-1) | 1,452 | $38.9K |
Who owns NRIX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Redmile Group, LLC13G, passive with 2 related filers | 8.1% | August 14, 2026 |
| Vestal Point Capital, LP13G, passive with 1 related filers | 7.8% | August 14, 2026 |
| Deep Track Capital, LP13G, passive with 2 related filers | 7.45% | August 14, 2026 |
| Baker Bros. Advisors LP13G, passive with 3 related filers | 7.2% | February 17, 2026 |
| Rubric Capital Management LP13G, passive with 1 related filers | 6.96% | August 14, 2026 |
| Fmr LLC13G, passive with 1 related filers | 5.4% | May 6, 2026 |
| Perceptive Advisors LLC13G, passive with 2 related filers | 5.3% | September 23, 2026 |
| T. Rowe Price Associates, Inc.13G, passive | 5.3% | August 14, 2026 |
| Vanguard Capital Management13G, passive | 5.03% | July 31, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 211 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 8,770,349 | -155,293 |
| Vestal Point Capital, LP | 8,050,000 | +1,550,000 |
| Deep Track Capital, LP | 7,736,455 | +1,391,211 |
| Rubric Capital Management LP | 7,227,778 | +4,753,893 |
| Fmr LLC | 5,485,215 | -56,056 |
| Morgan Stanley | 4,762,484 | -169,515 |
| State Street Corp | 4,677,244 | -463,951 |
| Baker Bros. Advisors LP | 4,658,556 | 0 |
| Vanguard Capital Management LLC | 4,495,529 | +68,417 |
| Perceptive Advisors LLC | 4,320,422 | +609,545 |
| Redmile Group, LLC | 4,073,787 | -3,659,021 |
| General Atlantic, L.P. | 3,032,185 | -1,069,680 |
| Geode Capital Management, LLC | 2,537,291 | +17,062 |
| Pictet Asset Management Holding SA | 2,351,232 | -374,906 |
| ARK Investment Management LLC | 1,793,196 | +72,061 |
| Capital World Investors | 1,787,916 | +894,589 |
| Trails Edge Capital Partners, LP | 1,573,220 | -170,000 |
| Vanguard Portfolio Management LLC | 1,482,861 | +380,595 |
| Citadel Advisors LLC | 1,477,019 | +133,319 |
| Soleus Capital Management, L.P. | 1,465,163 | +527,000 |
Insiders
4 insiders reported holding 181,353 shares in total, about $2.9M at the last price.
| Holder | Shares |
|---|---|
| Hansen GwennChief Scientific Officer | 123,452 |
| van Houte HansChief Financial Officer | 42,745 |
| Gregory Julia PDirector | 10,750 |
| Ring ChristineChief Legal Officer | 4,406 |
Questions about NRIX
What does Nurix Therapeutics, Inc. do?
Nurix Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as NRIX. Its shares trade on NASDAQ under the ticker NRIX.
What is Nurix Therapeutics, Inc.'s net worth?
Nurix Therapeutics, Inc. has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $968.3M on its balance sheet at August 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Nurix Therapeutics, Inc. profitable?
Yes. Over the twelve months to August 31, 2026 it reported net income of $294.9M on revenue of $701.9M, a net margin of 42.0%.
How much revenue does Nurix Therapeutics, Inc. make?
Over the twelve months to August 31, 2026 Nurix Therapeutics, Inc. reported revenue of $701.9M. That is 738.8% more than a year earlier.
When did Nurix Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 13, 2026. It covers the period to August 31, 2026. Its newest filing of any kind is the passive stake changed from November 5, 2026.
When is Nurix Therapeutics, Inc.'s next earnings report?
Nurix Therapeutics, Inc.'s next report is expected around January 27, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare NRIX with
Follow NRIX
Get an email when Nurix Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Nurix Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.